-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR Symposium

Benzinga·11/20/2026 14:05:05
Listen to the news
  • Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumor immunity.
  • CAPTN-3 antibodies combine an NKG2A arm that blocks an inhibitory immune checkpoint with a capped CD3 arm designed to penetrate into solid cancers and activate T cells only within the tumor microenvironment, distinguishing the platform from conventional T-cell engagers that activate T cells before reaching their target.
  • IM1240, targeting 5T4, an oncofetal antigen expressed on a wide range of cancers, demonstrated potent anti-tumor activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy, including a muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab.
  • NKG2A engagement is a key contributor to tumor killing, as demonstrated in studies using IM1240 and matched antibody variants in patient-derived cancer specimens, supporting the platform's strategy of targeting both innate and adaptive immune responses.
  • In non-human primates, CD3 capping markedly reduced cytokine release and extended systemic exposure compared with a non-capped variant, with an approximately 8-fold longer half-life and 16-fold greater exposure, further supporting the potential of IM1240 to combine potent anti-tumor activity with a broad therapeutic window.

REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

CAPTN-3 is Purple Biotech's platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform's lead candidate, targets 5T4.

The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.